News
Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...
Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...
Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
Novo Nordisk A/S (NYSE:NVO) is addressing these concerns in its new Phase III trials for CagriSema. The firm noted that Novo ...
New trial shows CagriSema leads to major weight loss and better glycaemic control in Type 2 diabetes.
CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.
Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved patient-reported outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results